Loading...
PHASE I TRIAL OF A BIVALENT GANGLIOSIDES VACCINE IN COMBINATION WITH β-GLUCAN: FOR HIGH-RISK NEUROBLASTOMA IN SECOND OR LATER REMISSION
BACKGROUND: To report on a phase I trial designed to find the maximally tolerated dose in children of the immunological adjuvant OPT-821 in a vaccine containing neuroblastoma-associated antigens (GD2 and GD3) (Clinicaltrials.gov NCT00911560). Secondary objectives were to obtain preliminary data on i...
Na minha lista:
| Udgivet i: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5592799/ https://ncbi.nlm.nih.gov/pubmed/24520094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1012 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|